drugset
drugset / Trial / NCT02841761

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

NCT02841761 ↗

Phase 1 Completed 20 enrolled Idorsia Pharmaceuticals Ltd.
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the effect of ACT-132577 on the pharmacokinetics of midazolam and 1-hydroxy midazolam and to evaluate the safety and tolerability of ACT-132577 when administered alone and in combination with midazolam.

Timeline

Start
2016-07-01
Primary completion
2016-09-01
Completion
2016-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprocitentan Small molecule 50 mg Oral
Subject Midazolam Small molecule 8 mg Oral

Indications

No indication recorded.